




RealRate

PHARMACEUTICAL 2015

Neurogene Inc
Rank 95 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Neurogene Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neurogene Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Neurogene Inc is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 325%, being 71% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	39,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,203
Liabilities, Non-Current	0
Other Assets	2,016
Other Compr. Net Income	-3.9
Other Expenses	-0.22
Other Liabilities	72
Other Net Income	-1,652
Other Revenues	0
Property and Equipment	105
Research and Development	18,079
Selling, General and Administrative Expense	4,296

Output Variable	Value in 1000 USD
Assets	41,423
Liabilities	5,276
Expenses	22,375
Revenues	0
Stockholders Equity	36,147
Net Income	-24,027
Comprehensive Net Income	-24,029
BaseVar	35,365
ECR before Limited Liability	235%
Economic Capital Ratio	325%